Gene therapy of cancer

Drugs of Today

Volumn 36, Issue 9, 2000, Pages 619-629

  Rochlitz, C F ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; DNA; GENE PRODUCT; LIPOSOME; VIRUS VECTOR;

CANCER; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DNA PROTEIN COMPLEX; DNA TRANSFER; DRUG EFFICACY; DRUG SAFETY; DRUG TUMOR LEVEL; ELECTROPORATION; EXPRESSION VECTOR; GENE GUN; GENE THERAPY; HUMAN; IMMUNOPOTENTIATION; INTRATUMORAL DRUG ADMINISTRATION; MICROINJECTION; NONHUMAN; ONCOGENE; PRECIPITATION; REVIEW; SUICIDE GENE; TRANSGENE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 0033791244     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.9.593779     Document Type: Review

References (40)

1. T lymphocyte-directed gene therapy for ADASCID: Initial trial results after 4 years
2. Gene therapy: A loss of innocence
3. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
4. Human gene therapy
5. Cancer gene therapy annual conference 1997: Trends and news
6. Gene therapy of cancer
7. Gene therapy for cancer: What have we done and where are we going?
8. Gene therapy: Promises, problems and prospects
9. Gene therapy of cancer
10. Nonviral gene therapy: The promise of genes as pharmaceutical products
11. Gene transfer into humans: Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
12. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
13. Genetic marking shows that Ph(+) cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
14. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
15. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation
16. Immune response against tumors
17. Clinical promise of tumour immunology
18. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells
19. Gene therapy study of cytokine-transfected xenogeneic cells (Vero-lL-2) in patiments with metastatic solid tumors
20. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
21. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
22. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
23. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression
24. Gene therapy for lung cancer and mesothelioma
25. Molecular biology of cancer: Oncogenes
26. Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC)
27. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
28. Tumor-suppressor p53: Implications for tumor development and prognosis
29. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
30. A phase I study of adenovirus mediated wild type p53 gene transfer in patients with advanced non-small cell lung cancer
31. Tolerance and safety of RPR/INGN 201, an adenoviral vector containing a p53 gene, administered intratumorally in 309 patients with advanced cancer enrolled in phase I and II studies worldwide
32. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
33. A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
34. New perspectives in clinical oncology from angiogenesis research
35. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
36. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
37. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
38. The rationale and future potential of angiogenesis inhibitors in neoplasia